Albumin-Bound Paclitaxel

01/01/2023 - "Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer."
10/05/2022 - "The antitumor efficacy of these two conjugates outperformed parent PTX formulation and Abraxane in nude mice bearing breast cancer cells MCF-7. "
07/01/2021 - "A commercial albumin-bound paclitaxel nano-formulation has been considered a gold standard against breast cancer. "
01/01/2018 - "Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer."
12/01/2017 - "Recently, the efficacy of nanoparticle albumin-bound paclitaxel (nab-PTX) for metastatic breast cancer was reported. "

07/23/2021 - "These studies show that a tumor-targeted oral formulation of PAC (FA-ExoPAC) significantly improved the overall efficacy and safety profile while providing a user-friendly, cost-effective alternative to bolus i.v. PAC and i.v. Abraxane."
10/05/2022 - "The conjugate S exhibited improved pharmacokinetic parameters and higher distribution extent in tumor sites than the parent PTX, Abraxane and the conjugate L. "
11/01/2023 - "However, the instability, chemoresistance, and lack of tumor microenvironment modulation of albumin-bound paclitaxel may lead to poor therapeutic efficacy in metastatic cancer patients. "
01/01/2022 - "Moreover, conjugate A completely eradicated all MCF-7 xenograft tumors without causing any obvious side effects and totally outperformed both the conventional DTX formulation and Abraxane in mice. "
01/01/2023 - "A retrospect study based on real-world data to observe metabolic function in cancer patients using albumin-bound paclitaxel."

09/01/2015 - "[Complete Remission after Weekly Intravenous Nanoparticle Albumin-Bound Paclitaxel in Elderly Patients with Non-Small-Cell Lung Cancer]."
08/01/2016 - "To observe the safety and short-term efficacy of sigle drug albumin-bound paclitaxel (ABP) in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC). "
01/01/2014 - "First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel."
11/01/2023 - "Efficacy and safety of nanoparticle albumin-bound paclitaxel in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials and observational studies."
07/01/2022 - "Phase II study of nanoparticle albumin-bound paclitaxel monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes (NLCTG1302)."

01/01/2022 - "SOX8 transcriptionally regulated EZH2, which reduced expression of SPARC by promoting the methylation of SPARC, thereby reducing the transport of albumin-bound paclitaxel in pancreatic cancer cells. "
08/28/2017 - "Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions."
05/01/2015 - "Nanoparticle albumin-bound-paclitaxel: a limited improvement under the current therapeutic paradigm of pancreatic cancer."
10/01/2014 - "Albumin-bound paclitaxel: a review of its use for the first-line combination treatment of metastatic pancreatic cancer."
06/21/2020 - "Photothermal augment stromal disrupting effects for enhanced Abraxane synergy chemotherapy in pancreatic cancer PDX mode."

04/01/2022 - "Some clinical studies suggest that albumin-bound paclitaxel combined with S-1 can be used in the first-line treatment of gastric cancer. "
02/18/2014 - "To evaluate the safety and efficacy of albumin-bound paclitaxel in patients with advanced gastric cancer (AGC). "
02/18/2014 - "[Efficacy of albumin-bound paclitaxel in advanced gastric cancer patients]."
02/18/2014 - "Additional phase I/II studies of albumin-bound paclitaxel in gastric cancer are warranted."
04/01/2022 - "Single-drug albumin-bound paclitaxel is one of the standard second-line treatments for advanced gastric cancer. "